	US 12,453,762 B2
	Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma
Madiha Derouazi, Grand-Saconnex (CH); and Elodie Belnoue, Geneva (CH)
Assigned to Amal Therapeutics SA, Geneva (CH)
Filed by Amal Therapeutics SA, Geneva (CH)
Filed on Dec. 22, 2021, as Appl. No. 17/558,906.
Application 17/558,906 is a continuation of application No. 15/557,651, abandoned, previously published as PCT/EP2016/000470, filed on Mar. 16, 2016.
Claims priority of application No. PCT/EP2015/000580 (WO), filed on Mar. 16, 2015; and application No. PCT/EP2015/002244 (WO), filed on Nov. 9, 2015.
Prior Publication US 2022/0175933 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); A61K 47/42 (2017.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 14/475 (2006.01); C07K 19/00 (2006.01); C12N 5/10 (2006.01)

CPC A61K 39/0011 (2013.01) [A61K 38/10 (2013.01); A61K 38/17 (2013.01); A61K 38/177 (2013.01); A61K 38/18 (2013.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); A61K 40/4273 (2025.01); A61K 40/4277 (2025.01); A61K 47/42 (2013.01); A61K 47/64 (2017.08); A61K 47/6425 (2017.08); A61K 47/6803 (2017.08); A61K 47/6811 (2017.08); A61K 47/6865 (2017.08); A61P 1/00 (2018.01); A61P 35/00 (2018.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/47 (2013.01); C07K 14/475 (2013.01); C07K 19/00 (2013.01); C12N 5/10 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/6031 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/10 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C12N 2710/16233 (2013.01); Y02A 50/30 (2018.01)]

26 Claims

1. A method for treating glioma in a subject in need thereof, the method comprising administering to the subject a complex comprising:

a) a cell penetrating peptide having an amino acid sequence consisting of SEQ ID NO: 6 (CPP/Z13);

b) at least one antigen or antigenic epitope, wherein the at least one antigen or antigenic epitope comprises at least one tumor epitope; and

c) at least one TLR peptide agonist, wherein the TLR peptide agonist is a TLR2 or TLR4 peptide agonist, having an amino acid sequence consisting of SEQ ID NO: 15,

wherein the components a)-c) are covalently linked.